BriaCell Therapeutics Corp. (BCTX) Cash from Investing Activities (2019 - 2026)

BriaCell Therapeutics has reported Cash from Investing Activities for 4 years, with the latest figure at -$16.0 million in Q2 2026.

• Quarterly Cash from Investing Activities fell 15141.0% year-over-year to -$16.0 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$16.2 million (down 2174.03% YoY) and the FY2025 annual result came in at -$7.6 million, down 1021.44% from the prior year.
• Cash from Investing Activities retreated to -$16.0 million in Q2 2026 per BCTX's latest filing, from $7.3 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $7.3 million in Q1 2026 and troughed at -$16.0 million in Q2 2026.
• A 3-year average of -$2.1 million and a median of -$90000.0 in 2024 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 9809.96% in 2026, down 15141.0% in 2026.
• Over 3 years, Cash from Investing Activities stood at -$75000.0 in 2024, then changed by 0.0% to -$75000.0 in 2025, then slumped by 21237.4% to -$16.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$16.0 million, $7.3 million, and -$75000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.